On December 10th, the "Top 50 Shanghai Startups with the Most Investment Potential in 2024" list was officially announced at the "Bund Finance·Shanghai International Equity Investment Forum." Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen") was honored to be included on the list, marking another recognition of Escugen's scientific and technological innovation capabilities and investment potential by the industry.

On December 3, 2024, Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen") announced that the company's independently developed innovative drug, ESG401 Injection, has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to conduct its second Phase III clinical study (ESG401-302). This study focuses on the treatment of locally advanced, recurrent, or metastatic PD-L1 negative triple-negative breast cancer (TNBC) that has not previously been treated with systemic therapy.